Home>

Products

Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Continue shopping Get Notified

Anti-IP-10 [PTEN]-AF488

Anti-IP-10 [PTEN]-AF488
Product Type: Reagents for Cytometry and Functional Assays
Format: Anti-IP-10, MDX1100, human variable region, rhesus IgG4 SC LALA Fc
Clone ID: [PTEN]
RRID: AB_2941331
Common Names: Anti-IP-10 [PTEN]-AF488 | aIP10_MDX1100_hosa_G4_SC_LALA_mamu | PTEN | PTENSCLALA | Eldelumab | AlexaFluor488 | PR-0088 | CAT-00103
Target: IP-10
Reactivity: Human (Homo sapiens) Rhesus Macaque (Macaca mulatta)
Applications: in vitro; flow cytometry
Description:

Recombinant anti-IP-10 engineered as a rhesus IgG4 with an SC stabilizing mutation, and effector function silencing LALA mutations conjugated with AlexaFluor488
Modifications: AF488
Restrictions: No
Sponsor: NIAID
How to cite (Methods): Anti-IP-10 [PTEN]-AF488 (NHPRR Cat#PR-0088, RRID:AB_2941331)
How to cite (Acknowledgments): The Anti-IP-10 [PTEN]-AF488 antibody (Cat#PR-0088, RRID:AB_2941331) used in this study was provided by the Nonhuman Primate Reagent Resource (NHPRR, RRID:SCR_012986), funded by NIAID U24 AI126683.

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.

CAN'T FIND EXACTLY WHAT YOUR RESEARCH REQUIRES?

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2025